Diana Thao Vi Tran, MD
Family Practice · Milpitas
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Sutter Bay Medical Foundation · Endeavor Health Medical Group
Hospitals listed: Swedish Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Tran’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Illinois 125079548Temporary Medical Permit · since 2022 · expires 2025-06-21Specialty on the licence: Family MedicineCancelledNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Swedish HospitalChicago, ILAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of NorthShore � Edward-Elmhurst Health, which runs 8 hospitalsPatients rate it 2 of 5 · 59% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.7 (11.1 to 14.5) · 1,394 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.323, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.6 (2.8 to 4.6) · 1,394 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Swedish Hospital
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 2 better, 5 the same, 2 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.7 (11.1 to 14.5) · 1,394 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.323 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 3.6 (2.8 to 4.6) · 1,394 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.92 (0 to 1.94) · 693 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 177.85 (120.01 to 235.69) · 35 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.3 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 121 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 287 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.2 · 384 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.3 · 1,775 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.38) · 3,651 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 3,849 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.6 (1.24 to 5.95) · 618 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.49 (0 to 3.13) · 135 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.98 (0.38 to 3.58) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.85 (0 to 14.36) · 158 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.29 (0.36 to 8.23) · 128 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.19 to 3.2) · 137 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.14) · 2,915 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.309 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.282 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.869 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.329 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 139 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.2 · 398 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 66.5 · 118 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17.9 · 324 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 41.9 · 391 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.4 · 483 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.6 (9.4 to 16.9) · 501 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.2) · 255 cases | No different | Jan 2024 – Dec 2024 |
What patients said (984 patients answered, 14% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 79% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 59% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 82% |
Drugs they prescribed that Part D paid
$13,244
Pharmacies billed $13,244 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 148) in 2024. At or below the middle of the specialty; the typical family practice clinician is at 2%.
130 generic and fewer than 11 brand-name prescriptions · $13,244 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lamotrigine | 22 | $185 | $8 |
| Amlodipine Besylate | 16 | $154 | $10 |
| Atorvastatin | 13 | $144 | $11 |
Year by year
| 2024 | 148 | 32 | 0% (0) | None | $13,244 |
| 2023 | 168 | 41 | None | 18% | $19,162 |
| 2022 | 54 | 29 | 0% (0) | None | $1,732 |
| 2021 | 11 | None | 0% (0) | None | $660 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Jardiance | 11 | $8,137 | $740 |
| Lamotrigine | 20 | $144 | $7 |
| Amlodipine Besylate | 14 | $53 | $4 |
Money from drug and device companies
$1,220 in 2025
| 2025 | 20 | 55 | None | $1,220 |
| 2024 | 1 | 1 | None | $109 |
| 2023 | 2 | 3 | None | $42 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lilly USA | Mounjaro | $193 | 9 payments
|
| Novo Nordisk | Rybelsus | $179 | 8 payments
|
| Abbvie | Vraylar | $176 | 7 payments
|
| Otsuka America Pharmaceutical | Rexulti | $102 | 5 payments
|
| Pfizer | Prevnar 20 | $98 | 4 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $72 | 3 payments
|
See all 55 published payments
| Xeris Pharmaceuticals | Meals · 2025-09-30 | Gvoke Hypopen | $24 |
| Abbvie | Meals · 2025-09-29 | Ubrelvy | $22 |
| Novo Nordisk | Meals · 2025-09-25 | Wegovy | $23 |
| Novo Nordisk | Meals · 2025-09-24 | Wegovy | $23 |
| Lundbeck | Meals · 2025-09-23 | Rexulti | $16 |
| Lilly USA | Meals · 2025-09-17 | Mounjaro | $28 |
| Lundbeck | Meals · 2025-09-12 | Rexulti | $30 |
| Xeris Pharmaceuticals | Meals · 2025-09-09 | Gvoke Hypopen | $24 |
| Lilly USA | Meals · 2025-09-03 | None | $18 |
| Novo Nordisk | Meals · 2025-09-02 | Rybelsus | $30 |
| Lundbeck | Meals · 2025-08-29 | Rexulti | $16 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-28 | Flumist Quadrivalent | $26 |
| Corcept Therapeutics | Meals · 2025-08-27 | Korlym | $24 |
| Pfizer | Meals · 2025-08-27 | None | $24 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-08-26 | Kerendia | $21 |
| Madrigal Pharmaceuticals | Meals · 2025-08-26 | Rezdiffra | $20 |
| Lilly USA | Meals · 2025-08-23 | Mounjaro | $24 |
| Xeris Pharmaceuticals | Meals · 2025-08-20 | Gvoke Hypopen | $24 |
| ViiV Healthcare | Meals · 2025-08-14 | Apretude | $30 |
| Otsuka America Pharmaceutical | Meals · 2025-08-13 | Rexulti | $29 |
| Lilly USA | Meals · 2025-08-05 | Mounjaro | $24 |
| Lilly USA | Meals · 2025-07-29 | Amyvid | $10 |
| Otsuka America Pharmaceutical | Meals · 2025-07-25 | Rexulti | $15 |
| Lilly USA | Meals · 2025-07-23 | Mounjaro | $18 |
| Novo Nordisk | Meals · 2025-07-16 | Rybelsus | $25 |
| Novo Nordisk | Meals · 2025-06-25 | Wegovy | $19 |
| Lilly USA | Meals · 2025-06-18 | Mounjaro | $18 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-16 | None | $18 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-06-12 | Caplyta | $17 |
| Novo Nordisk | Meals · 2025-06-11 | Rybelsus | $23 |
| Abbvie | Meals · 2025-06-10 | Vraylar | $10 |
| Abbvie | Meals · 2025-06-10 | Vraylar | $2 |
| Abbvie | Meals · 2025-06-10 | Vraylar | $1 |
| Lilly USA | Meals · 2025-06-07 | Mounjaro | $29 |
| Abbvie | Meals · 2025-05-30 | Vraylar | $23 |
| Lilly USA | Meals · 2025-05-15 | Mounjaro | $26 |
| Abbvie | Meals · 2025-05-15 | Vraylar | $108 |
| Abbvie | Meals · 2025-05-14 | Vraylar | $10 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-06 | Jardiance | $28 |
| C2N Diagnostics | Meals · 2025-04-30 | Precivityad2 | $19 |
| Amgen | Meals · 2025-04-29 | Repatha | $14 |
| Novo Nordisk | Meals · 2025-04-24 | Ozempic | $18 |
| Sumitomo Pharma America | Meals · 2025-04-10 | Gemtesa | $28 |
| Merck Sharp & Dohme | Meals · 2025-04-10 | Capvaxive | $21 |
| Pfizer | Meals · 2025-04-09 | None | $24 |
| Otsuka America Pharmaceutical | Meals · 2025-04-01 | Rexulti | $18 |
| Pfizer | Meals · 2025-03-27 | None | $20 |
| Amgen | Meals · 2025-03-25 | Otezla | $16 |
| Exact Sciences | Meals · 2025-03-19 | Cologuard Collection Kit | $25 |
| Pfizer | Meals · 2025-03-18 | Prevnar 20 | $30 |
| Amgen | Meals · 2025-03-13 | Evenity | $17 |
| Novo Nordisk | Meals · 2025-03-07 | Ozempic | $19 |
| Otsuka America Pharmaceutical | Meals · 2025-03-05 | Rexulti | $22 |
| Cranial Technologies | Meals · 2025-02-28 | Doc Band | $14 |
| Otsuka America Pharmaceutical | Meals · 2025-02-27 | Rexulti | $19 |
See earlier years (2024, 2023)
2024: $109
| Novo Nordisk | None | $109 | 1 payment
|
2023: $42
| LeMaitre Vascular | Xenosure Biologic Patch | $23 | 2 payments
|
| Organon | Nexplanon | $19 | 1 payment
|
Professional record
- NPI
- 1912571829
- Licence
- IL 125079548Illinois 125079548: Cancelled
- Group
- Sutter Bay Medical Foundation · Endeavor Health Medical Group
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Family medicine (207Q00000X)
- Mailing address
- 100 N Milpitas Blvd, Milpitas, CA, 95035
- NPI first listed
- 2021-05-14
- NPI last updated
- 2025-12-15
- NPI record certified
- 2025-12-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3249 Oak Park Ave, Berwyn, IL, 60402 · 5215 N California Ave Ste 602, Chicago, IL, 60625 · 31700 Temecula Pkwy, Temecula, CA, 92592